nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—Nucleic Acid Synthesis Inhibitors—Azathioprine—systemic scleroderma	0.669	1	CiPCiCtD
Capecitabine—CES1—Mycophenolate mofetil—systemic scleroderma	0.116	0.596	CbGbCtD
Capecitabine—TYMS—Methotrexate—systemic scleroderma	0.0594	0.306	CbGbCtD
Capecitabine—CYP2C9—Leflunomide—systemic scleroderma	0.019	0.0978	CbGbCtD
Capecitabine—CYP2C9—cardial valve—systemic scleroderma	0.00629	0.274	CbGeAlD
Capecitabine—TYMP—endothelium—systemic scleroderma	0.00213	0.0926	CbGeAlD
Capecitabine—TYMP—blood vessel—systemic scleroderma	0.00196	0.0854	CbGeAlD
Capecitabine—CDA—tendon—systemic scleroderma	0.00115	0.0499	CbGeAlD
Capecitabine—DPYD—lung—systemic scleroderma	0.00105	0.0456	CbGeAlD
Capecitabine—TYMP—connective tissue—systemic scleroderma	0.00101	0.0438	CbGeAlD
Capecitabine—TYMP—smooth muscle tissue—systemic scleroderma	0.000921	0.04	CbGeAlD
Capecitabine—CES1—connective tissue—systemic scleroderma	0.000869	0.0378	CbGeAlD
Capecitabine—TYMS—connective tissue—systemic scleroderma	0.000863	0.0375	CbGeAlD
Capecitabine—TYMS—smooth muscle tissue—systemic scleroderma	0.00079	0.0343	CbGeAlD
Capecitabine—TYMS—skin of body—systemic scleroderma	0.00078	0.0339	CbGeAlD
Capecitabine—TYMP—digestive system—systemic scleroderma	0.000727	0.0316	CbGeAlD
Capecitabine—TYMP—tendon—systemic scleroderma	0.000692	0.0301	CbGeAlD
Capecitabine—CES1—digestive system—systemic scleroderma	0.000627	0.0273	CbGeAlD
Capecitabine—TYMS—digestive system—systemic scleroderma	0.000624	0.0271	CbGeAlD
Capecitabine—TYMP—lung—systemic scleroderma	0.000607	0.0264	CbGeAlD
Capecitabine—TYMS—tendon—systemic scleroderma	0.000593	0.0258	CbGeAlD
Capecitabine—CES1—lung—systemic scleroderma	0.000524	0.0228	CbGeAlD
Capecitabine—TYMS—lung—systemic scleroderma	0.000521	0.0226	CbGeAlD
Capecitabine—CYP2C9—digestive system—systemic scleroderma	0.000272	0.0118	CbGeAlD
Capecitabine—TYMS—Clobetasol propionate—Mometasone—systemic scleroderma	0.000182	0.117	CbGdCrCtD
Capecitabine—TYMS—Flunisolide—Mometasone—systemic scleroderma	0.00018	0.115	CbGdCrCtD
Capecitabine—TYMS—Triamcinolone—Mometasone—systemic scleroderma	0.000178	0.114	CbGdCrCtD
Capecitabine—TYMS—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000174	0.111	CbGdCrCtD
Capecitabine—TYMS—Diflorasone—Mometasone—systemic scleroderma	0.000164	0.105	CbGdCrCtD
Capecitabine—TYMS—Budesonide—Mometasone—systemic scleroderma	0.000144	0.0923	CbGdCrCtD
Capecitabine—TYMS—Clobetasol propionate—Prednisone—systemic scleroderma	9.95e-05	0.0637	CbGdCrCtD
Capecitabine—TYMS—Flunisolide—Prednisone—systemic scleroderma	9.82e-05	0.0629	CbGdCrCtD
Capecitabine—TYMS—Triamcinolone—Prednisone—systemic scleroderma	9.72e-05	0.0623	CbGdCrCtD
Capecitabine—TYMS—Diflorasone—Prednisone—systemic scleroderma	8.96e-05	0.0574	CbGdCrCtD
Capecitabine—TYMS—Budesonide—Prednisone—systemic scleroderma	7.85e-05	0.0503	CbGdCrCtD
Capecitabine—TYMS—Danazol—Prednisone—systemic scleroderma	7.52e-05	0.0482	CbGdCrCtD
Capecitabine—Abdominal pain—Leflunomide—systemic scleroderma	3.6e-05	0.000319	CcSEcCtD
Capecitabine—Body temperature increased—Leflunomide—systemic scleroderma	3.6e-05	0.000319	CcSEcCtD
Capecitabine—Acute coronary syndrome—Prednisone—systemic scleroderma	3.59e-05	0.000319	CcSEcCtD
Capecitabine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	3.58e-05	0.000318	CcSEcCtD
Capecitabine—Myalgia—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.000317	CcSEcCtD
Capecitabine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.000317	CcSEcCtD
Capecitabine—Chest pain—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.000317	CcSEcCtD
Capecitabine—Myocardial infarction—Prednisone—systemic scleroderma	3.57e-05	0.000317	CcSEcCtD
Capecitabine—Neuropathy peripheral—Prednisone—systemic scleroderma	3.57e-05	0.000317	CcSEcCtD
Capecitabine—Breast disorder—Methotrexate—systemic scleroderma	3.57e-05	0.000317	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	3.56e-05	0.000316	CcSEcCtD
Capecitabine—Anxiety—Mycophenolate mofetil—systemic scleroderma	3.56e-05	0.000316	CcSEcCtD
Capecitabine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	3.55e-05	0.000316	CcSEcCtD
Capecitabine—Hypersensitivity—Azathioprine—systemic scleroderma	3.55e-05	0.000315	CcSEcCtD
Capecitabine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	3.55e-05	0.000315	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	3.55e-05	0.000315	CcSEcCtD
Capecitabine—Insomnia—Lisinopril—systemic scleroderma	3.53e-05	0.000314	CcSEcCtD
Capecitabine—Discomfort—Mycophenolate mofetil—systemic scleroderma	3.53e-05	0.000313	CcSEcCtD
Capecitabine—Paraesthesia—Lisinopril—systemic scleroderma	3.51e-05	0.000312	CcSEcCtD
Capecitabine—Vomiting—Captopril—systemic scleroderma	3.51e-05	0.000312	CcSEcCtD
Capecitabine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	3.49e-05	0.00031	CcSEcCtD
Capecitabine—Dyspnoea—Lisinopril—systemic scleroderma	3.48e-05	0.00031	CcSEcCtD
Capecitabine—Rash—Captopril—systemic scleroderma	3.48e-05	0.000309	CcSEcCtD
Capecitabine—Dermatitis—Captopril—systemic scleroderma	3.48e-05	0.000309	CcSEcCtD
Capecitabine—Headache—Captopril—systemic scleroderma	3.46e-05	0.000307	CcSEcCtD
Capecitabine—Confusional state—Mycophenolate mofetil—systemic scleroderma	3.45e-05	0.000307	CcSEcCtD
Capecitabine—Dyspepsia—Lisinopril—systemic scleroderma	3.44e-05	0.000306	CcSEcCtD
Capecitabine—Abdominal pain—Mycophenolic acid—systemic scleroderma	3.43e-05	0.000305	CcSEcCtD
Capecitabine—Body temperature increased—Mycophenolic acid—systemic scleroderma	3.43e-05	0.000305	CcSEcCtD
Capecitabine—Oedema—Mycophenolate mofetil—systemic scleroderma	3.42e-05	0.000304	CcSEcCtD
Capecitabine—Asthma—Methotrexate—systemic scleroderma	3.41e-05	0.000303	CcSEcCtD
Capecitabine—Infection—Mycophenolate mofetil—systemic scleroderma	3.4e-05	0.000302	CcSEcCtD
Capecitabine—Decreased appetite—Lisinopril—systemic scleroderma	3.4e-05	0.000302	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	3.37e-05	0.0003	CcSEcCtD
Capecitabine—Fatigue—Lisinopril—systemic scleroderma	3.37e-05	0.000299	CcSEcCtD
Capecitabine—Shock—Mycophenolate mofetil—systemic scleroderma	3.37e-05	0.000299	CcSEcCtD
Capecitabine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	3.36e-05	0.000298	CcSEcCtD
Capecitabine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	3.35e-05	0.000298	CcSEcCtD
Capecitabine—Hypersensitivity—Leflunomide—systemic scleroderma	3.35e-05	0.000298	CcSEcCtD
Capecitabine—Pain—Lisinopril—systemic scleroderma	3.34e-05	0.000297	CcSEcCtD
Capecitabine—Constipation—Lisinopril—systemic scleroderma	3.34e-05	0.000297	CcSEcCtD
Capecitabine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	3.34e-05	0.000297	CcSEcCtD
Capecitabine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	3.33e-05	0.000295	CcSEcCtD
Capecitabine—Bradycardia—Prednisone—systemic scleroderma	3.33e-05	0.000295	CcSEcCtD
Capecitabine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	3.31e-05	0.000294	CcSEcCtD
Capecitabine—Diarrhoea—Azathioprine—systemic scleroderma	3.3e-05	0.000293	CcSEcCtD
Capecitabine—Haemoglobin—Prednisone—systemic scleroderma	3.28e-05	0.000292	CcSEcCtD
Capecitabine—Nausea—Captopril—systemic scleroderma	3.28e-05	0.000291	CcSEcCtD
Capecitabine—Abdominal discomfort—Methotrexate—systemic scleroderma	3.27e-05	0.00029	CcSEcCtD
Capecitabine—Haemorrhage—Prednisone—systemic scleroderma	3.27e-05	0.00029	CcSEcCtD
Capecitabine—Anorexia—Mycophenolate mofetil—systemic scleroderma	3.26e-05	0.00029	CcSEcCtD
Capecitabine—Asthenia—Leflunomide—systemic scleroderma	3.26e-05	0.00029	CcSEcCtD
Capecitabine—Pancytopenia—Methotrexate—systemic scleroderma	3.24e-05	0.000288	CcSEcCtD
Capecitabine—Feeling abnormal—Lisinopril—systemic scleroderma	3.22e-05	0.000286	CcSEcCtD
Capecitabine—Pruritus—Leflunomide—systemic scleroderma	3.22e-05	0.000286	CcSEcCtD
Capecitabine—Connective tissue disorder—Prednisone—systemic scleroderma	3.21e-05	0.000285	CcSEcCtD
Capecitabine—Hypotension—Mycophenolate mofetil—systemic scleroderma	3.2e-05	0.000284	CcSEcCtD
Capecitabine—Gastrointestinal pain—Lisinopril—systemic scleroderma	3.2e-05	0.000284	CcSEcCtD
Capecitabine—Neutropenia—Methotrexate—systemic scleroderma	3.19e-05	0.000283	CcSEcCtD
Capecitabine—Dysuria—Methotrexate—systemic scleroderma	3.19e-05	0.000283	CcSEcCtD
Capecitabine—Dizziness—Azathioprine—systemic scleroderma	3.18e-05	0.000283	CcSEcCtD
Capecitabine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	3.17e-05	0.000282	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	3.12e-05	0.000277	CcSEcCtD
Capecitabine—Photosensitivity reaction—Methotrexate—systemic scleroderma	3.11e-05	0.000277	CcSEcCtD
Capecitabine—Asthenia—Mycophenolic acid—systemic scleroderma	3.11e-05	0.000277	CcSEcCtD
Capecitabine—Diarrhoea—Leflunomide—systemic scleroderma	3.11e-05	0.000276	CcSEcCtD
Capecitabine—Urticaria—Lisinopril—systemic scleroderma	3.1e-05	0.000276	CcSEcCtD
Capecitabine—Insomnia—Mycophenolate mofetil—systemic scleroderma	3.1e-05	0.000275	CcSEcCtD
Capecitabine—Abdominal pain—Lisinopril—systemic scleroderma	3.09e-05	0.000274	CcSEcCtD
Capecitabine—Body temperature increased—Lisinopril—systemic scleroderma	3.09e-05	0.000274	CcSEcCtD
Capecitabine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	3.07e-05	0.000273	CcSEcCtD
Capecitabine—Pruritus—Mycophenolic acid—systemic scleroderma	3.07e-05	0.000273	CcSEcCtD
Capecitabine—Vomiting—Azathioprine—systemic scleroderma	3.06e-05	0.000272	CcSEcCtD
Capecitabine—Pneumonia—Methotrexate—systemic scleroderma	3.06e-05	0.000272	CcSEcCtD
Capecitabine—Eye disorder—Prednisone—systemic scleroderma	3.05e-05	0.000271	CcSEcCtD
Capecitabine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000271	CcSEcCtD
Capecitabine—Infestation NOS—Methotrexate—systemic scleroderma	3.04e-05	0.00027	CcSEcCtD
Capecitabine—Infestation—Methotrexate—systemic scleroderma	3.04e-05	0.00027	CcSEcCtD
Capecitabine—Rash—Azathioprine—systemic scleroderma	3.04e-05	0.00027	CcSEcCtD
Capecitabine—Dermatitis—Azathioprine—systemic scleroderma	3.03e-05	0.000269	CcSEcCtD
Capecitabine—Depression—Methotrexate—systemic scleroderma	3.03e-05	0.000269	CcSEcCtD
Capecitabine—Flushing—Prednisone—systemic scleroderma	3.03e-05	0.000269	CcSEcCtD
Capecitabine—Headache—Azathioprine—systemic scleroderma	3.02e-05	0.000268	CcSEcCtD
Capecitabine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	3.02e-05	0.000268	CcSEcCtD
Capecitabine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	3.01e-05	0.000268	CcSEcCtD
Capecitabine—Dizziness—Leflunomide—systemic scleroderma	3.01e-05	0.000267	CcSEcCtD
Capecitabine—Renal failure—Methotrexate—systemic scleroderma	2.99e-05	0.000266	CcSEcCtD
Capecitabine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	2.98e-05	0.000264	CcSEcCtD
Capecitabine—Diarrhoea—Mycophenolic acid—systemic scleroderma	2.97e-05	0.000264	CcSEcCtD
Capecitabine—Stomatitis—Methotrexate—systemic scleroderma	2.96e-05	0.000263	CcSEcCtD
Capecitabine—Angiopathy—Prednisone—systemic scleroderma	2.96e-05	0.000263	CcSEcCtD
Capecitabine—Conjunctivitis—Methotrexate—systemic scleroderma	2.96e-05	0.000263	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	2.96e-05	0.000263	CcSEcCtD
Capecitabine—Immune system disorder—Prednisone—systemic scleroderma	2.95e-05	0.000262	CcSEcCtD
Capecitabine—Pain—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.00026	CcSEcCtD
Capecitabine—Constipation—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.00026	CcSEcCtD
Capecitabine—Arrhythmia—Prednisone—systemic scleroderma	2.92e-05	0.000259	CcSEcCtD
Capecitabine—Haematuria—Methotrexate—systemic scleroderma	2.9e-05	0.000258	CcSEcCtD
Capecitabine—Vomiting—Leflunomide—systemic scleroderma	2.89e-05	0.000257	CcSEcCtD
Capecitabine—Alopecia—Prednisone—systemic scleroderma	2.89e-05	0.000256	CcSEcCtD
Capecitabine—Hypersensitivity—Lisinopril—systemic scleroderma	2.88e-05	0.000256	CcSEcCtD
Capecitabine—Hepatobiliary disease—Methotrexate—systemic scleroderma	2.88e-05	0.000256	CcSEcCtD
Capecitabine—Dizziness—Mycophenolic acid—systemic scleroderma	2.87e-05	0.000255	CcSEcCtD
Capecitabine—Epistaxis—Methotrexate—systemic scleroderma	2.87e-05	0.000255	CcSEcCtD
Capecitabine—Rash—Leflunomide—systemic scleroderma	2.87e-05	0.000255	CcSEcCtD
Capecitabine—Dermatitis—Leflunomide—systemic scleroderma	2.86e-05	0.000255	CcSEcCtD
Capecitabine—Mental disorder—Prednisone—systemic scleroderma	2.86e-05	0.000254	CcSEcCtD
Capecitabine—Nausea—Azathioprine—systemic scleroderma	2.86e-05	0.000254	CcSEcCtD
Capecitabine—Headache—Leflunomide—systemic scleroderma	2.85e-05	0.000253	CcSEcCtD
Capecitabine—Erythema—Prednisone—systemic scleroderma	2.84e-05	0.000253	CcSEcCtD
Capecitabine—Malnutrition—Prednisone—systemic scleroderma	2.84e-05	0.000253	CcSEcCtD
Capecitabine—Agranulocytosis—Methotrexate—systemic scleroderma	2.84e-05	0.000252	CcSEcCtD
Capecitabine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	2.82e-05	0.000251	CcSEcCtD
Capecitabine—Asthenia—Lisinopril—systemic scleroderma	2.8e-05	0.000249	CcSEcCtD
Capecitabine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	2.8e-05	0.000249	CcSEcCtD
Capecitabine—Pruritus—Lisinopril—systemic scleroderma	2.76e-05	0.000246	CcSEcCtD
Capecitabine—Vomiting—Mycophenolic acid—systemic scleroderma	2.76e-05	0.000245	CcSEcCtD
Capecitabine—Haemoglobin—Methotrexate—systemic scleroderma	2.74e-05	0.000244	CcSEcCtD
Capecitabine—Rash—Mycophenolic acid—systemic scleroderma	2.74e-05	0.000243	CcSEcCtD
Capecitabine—Dermatitis—Mycophenolic acid—systemic scleroderma	2.73e-05	0.000243	CcSEcCtD
Capecitabine—Hepatitis—Methotrexate—systemic scleroderma	2.73e-05	0.000243	CcSEcCtD
Capecitabine—Haemorrhage—Methotrexate—systemic scleroderma	2.73e-05	0.000243	CcSEcCtD
Capecitabine—Urticaria—Mycophenolate mofetil—systemic scleroderma	2.72e-05	0.000242	CcSEcCtD
Capecitabine—Headache—Mycophenolic acid—systemic scleroderma	2.72e-05	0.000241	CcSEcCtD
Capecitabine—Pharyngitis—Methotrexate—systemic scleroderma	2.71e-05	0.000241	CcSEcCtD
Capecitabine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	2.71e-05	0.00024	CcSEcCtD
Capecitabine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	2.71e-05	0.00024	CcSEcCtD
Capecitabine—Nausea—Leflunomide—systemic scleroderma	2.7e-05	0.00024	CcSEcCtD
Capecitabine—Urinary tract disorder—Methotrexate—systemic scleroderma	2.7e-05	0.00024	CcSEcCtD
Capecitabine—Vision blurred—Prednisone—systemic scleroderma	2.68e-05	0.000238	CcSEcCtD
Capecitabine—Urethral disorder—Methotrexate—systemic scleroderma	2.68e-05	0.000238	CcSEcCtD
Capecitabine—Diarrhoea—Lisinopril—systemic scleroderma	2.67e-05	0.000238	CcSEcCtD
Capecitabine—Ill-defined disorder—Prednisone—systemic scleroderma	2.64e-05	0.000234	CcSEcCtD
Capecitabine—Visual impairment—Methotrexate—systemic scleroderma	2.63e-05	0.000234	CcSEcCtD
Capecitabine—Anaemia—Prednisone—systemic scleroderma	2.63e-05	0.000233	CcSEcCtD
Capecitabine—Dizziness—Lisinopril—systemic scleroderma	2.58e-05	0.00023	CcSEcCtD
Capecitabine—Erythema multiforme—Methotrexate—systemic scleroderma	2.58e-05	0.000229	CcSEcCtD
Capecitabine—Nausea—Mycophenolic acid—systemic scleroderma	2.58e-05	0.000229	CcSEcCtD
Capecitabine—Malaise—Prednisone—systemic scleroderma	2.56e-05	0.000228	CcSEcCtD
Capecitabine—Vertigo—Prednisone—systemic scleroderma	2.55e-05	0.000227	CcSEcCtD
Capecitabine—Eye disorder—Methotrexate—systemic scleroderma	2.55e-05	0.000227	CcSEcCtD
Capecitabine—Syncope—Prednisone—systemic scleroderma	2.55e-05	0.000227	CcSEcCtD
Capecitabine—Tinnitus—Methotrexate—systemic scleroderma	2.55e-05	0.000226	CcSEcCtD
Capecitabine—Cardiac disorder—Methotrexate—systemic scleroderma	2.53e-05	0.000225	CcSEcCtD
Capecitabine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	2.52e-05	0.000224	CcSEcCtD
Capecitabine—Loss of consciousness—Prednisone—systemic scleroderma	2.5e-05	0.000222	CcSEcCtD
Capecitabine—Vomiting—Lisinopril—systemic scleroderma	2.48e-05	0.000221	CcSEcCtD
Capecitabine—Angiopathy—Methotrexate—systemic scleroderma	2.48e-05	0.00022	CcSEcCtD
Capecitabine—Immune system disorder—Methotrexate—systemic scleroderma	2.47e-05	0.000219	CcSEcCtD
Capecitabine—Rash—Lisinopril—systemic scleroderma	2.46e-05	0.000219	CcSEcCtD
Capecitabine—Dermatitis—Lisinopril—systemic scleroderma	2.46e-05	0.000219	CcSEcCtD
Capecitabine—Mediastinal disorder—Methotrexate—systemic scleroderma	2.46e-05	0.000219	CcSEcCtD
Capecitabine—Asthenia—Mycophenolate mofetil—systemic scleroderma	2.46e-05	0.000218	CcSEcCtD
Capecitabine—Hypertension—Prednisone—systemic scleroderma	2.46e-05	0.000218	CcSEcCtD
Capecitabine—Chills—Methotrexate—systemic scleroderma	2.45e-05	0.000218	CcSEcCtD
Capecitabine—Headache—Lisinopril—systemic scleroderma	2.45e-05	0.000217	CcSEcCtD
Capecitabine—Pruritus—Mycophenolate mofetil—systemic scleroderma	2.42e-05	0.000215	CcSEcCtD
Capecitabine—Myalgia—Prednisone—systemic scleroderma	2.42e-05	0.000215	CcSEcCtD
Capecitabine—Arthralgia—Prednisone—systemic scleroderma	2.42e-05	0.000215	CcSEcCtD
Capecitabine—Anxiety—Prednisone—systemic scleroderma	2.41e-05	0.000214	CcSEcCtD
Capecitabine—Alopecia—Methotrexate—systemic scleroderma	2.41e-05	0.000214	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	2.4e-05	0.000214	CcSEcCtD
Capecitabine—Discomfort—Prednisone—systemic scleroderma	2.39e-05	0.000213	CcSEcCtD
Capecitabine—Mental disorder—Methotrexate—systemic scleroderma	2.39e-05	0.000212	CcSEcCtD
Capecitabine—Erythema—Methotrexate—systemic scleroderma	2.38e-05	0.000211	CcSEcCtD
Capecitabine—Malnutrition—Methotrexate—systemic scleroderma	2.38e-05	0.000211	CcSEcCtD
Capecitabine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	2.34e-05	0.000208	CcSEcCtD
Capecitabine—Dysgeusia—Methotrexate—systemic scleroderma	2.33e-05	0.000207	CcSEcCtD
Capecitabine—Nausea—Lisinopril—systemic scleroderma	2.32e-05	0.000206	CcSEcCtD
Capecitabine—Oedema—Prednisone—systemic scleroderma	2.32e-05	0.000206	CcSEcCtD
Capecitabine—Infection—Prednisone—systemic scleroderma	2.31e-05	0.000205	CcSEcCtD
Capecitabine—Back pain—Methotrexate—systemic scleroderma	2.3e-05	0.000204	CcSEcCtD
Capecitabine—Shock—Prednisone—systemic scleroderma	2.28e-05	0.000203	CcSEcCtD
Capecitabine—Nervous system disorder—Prednisone—systemic scleroderma	2.28e-05	0.000202	CcSEcCtD
Capecitabine—Tachycardia—Prednisone—systemic scleroderma	2.27e-05	0.000201	CcSEcCtD
Capecitabine—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.26e-05	0.000201	CcSEcCtD
Capecitabine—Skin disorder—Prednisone—systemic scleroderma	2.25e-05	0.0002	CcSEcCtD
Capecitabine—Hyperhidrosis—Prednisone—systemic scleroderma	2.24e-05	0.000199	CcSEcCtD
Capecitabine—Vision blurred—Methotrexate—systemic scleroderma	2.24e-05	0.000199	CcSEcCtD
Capecitabine—Anorexia—Prednisone—systemic scleroderma	2.21e-05	0.000197	CcSEcCtD
Capecitabine—Ill-defined disorder—Methotrexate—systemic scleroderma	2.21e-05	0.000196	CcSEcCtD
Capecitabine—Anaemia—Methotrexate—systemic scleroderma	2.2e-05	0.000195	CcSEcCtD
Capecitabine—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.18e-05	0.000193	CcSEcCtD
Capecitabine—Rash—Mycophenolate mofetil—systemic scleroderma	2.16e-05	0.000192	CcSEcCtD
Capecitabine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.16e-05	0.000192	CcSEcCtD
Capecitabine—Headache—Mycophenolate mofetil—systemic scleroderma	2.15e-05	0.000191	CcSEcCtD
Capecitabine—Malaise—Methotrexate—systemic scleroderma	2.14e-05	0.00019	CcSEcCtD
Capecitabine—Vertigo—Methotrexate—systemic scleroderma	2.14e-05	0.00019	CcSEcCtD
Capecitabine—Leukopenia—Methotrexate—systemic scleroderma	2.13e-05	0.000189	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.11e-05	0.000188	CcSEcCtD
Capecitabine—Insomnia—Prednisone—systemic scleroderma	2.1e-05	0.000186	CcSEcCtD
Capecitabine—Paraesthesia—Prednisone—systemic scleroderma	2.08e-05	0.000185	CcSEcCtD
Capecitabine—Cough—Methotrexate—systemic scleroderma	2.07e-05	0.000184	CcSEcCtD
Capecitabine—Dyspepsia—Prednisone—systemic scleroderma	2.04e-05	0.000181	CcSEcCtD
Capecitabine—Nausea—Mycophenolate mofetil—systemic scleroderma	2.03e-05	0.000181	CcSEcCtD
Capecitabine—Arthralgia—Methotrexate—systemic scleroderma	2.02e-05	0.00018	CcSEcCtD
Capecitabine—Myalgia—Methotrexate—systemic scleroderma	2.02e-05	0.00018	CcSEcCtD
Capecitabine—Chest pain—Methotrexate—systemic scleroderma	2.02e-05	0.00018	CcSEcCtD
Capecitabine—Decreased appetite—Prednisone—systemic scleroderma	2.02e-05	0.000179	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.01e-05	0.000179	CcSEcCtD
Capecitabine—Fatigue—Prednisone—systemic scleroderma	2e-05	0.000178	CcSEcCtD
Capecitabine—Discomfort—Methotrexate—systemic scleroderma	2e-05	0.000178	CcSEcCtD
Capecitabine—Constipation—Prednisone—systemic scleroderma	1.98e-05	0.000176	CcSEcCtD
Capecitabine—Confusional state—Methotrexate—systemic scleroderma	1.96e-05	0.000174	CcSEcCtD
Capecitabine—Infection—Methotrexate—systemic scleroderma	1.93e-05	0.000171	CcSEcCtD
Capecitabine—Feeling abnormal—Prednisone—systemic scleroderma	1.91e-05	0.00017	CcSEcCtD
Capecitabine—Nervous system disorder—Methotrexate—systemic scleroderma	1.9e-05	0.000169	CcSEcCtD
Capecitabine—Thrombocytopenia—Methotrexate—systemic scleroderma	1.9e-05	0.000169	CcSEcCtD
Capecitabine—Gastrointestinal pain—Prednisone—systemic scleroderma	1.9e-05	0.000169	CcSEcCtD
Capecitabine—Skin disorder—Methotrexate—systemic scleroderma	1.88e-05	0.000167	CcSEcCtD
Capecitabine—Hyperhidrosis—Methotrexate—systemic scleroderma	1.88e-05	0.000167	CcSEcCtD
Capecitabine—Anorexia—Methotrexate—systemic scleroderma	1.85e-05	0.000164	CcSEcCtD
Capecitabine—Urticaria—Prednisone—systemic scleroderma	1.84e-05	0.000164	CcSEcCtD
Capecitabine—Abdominal pain—Prednisone—systemic scleroderma	1.83e-05	0.000163	CcSEcCtD
Capecitabine—Body temperature increased—Prednisone—systemic scleroderma	1.83e-05	0.000163	CcSEcCtD
Capecitabine—Hypotension—Methotrexate—systemic scleroderma	1.81e-05	0.000161	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	1.77e-05	0.000157	CcSEcCtD
Capecitabine—Insomnia—Methotrexate—systemic scleroderma	1.75e-05	0.000156	CcSEcCtD
Capecitabine—Paraesthesia—Methotrexate—systemic scleroderma	1.74e-05	0.000155	CcSEcCtD
Capecitabine—Dyspnoea—Methotrexate—systemic scleroderma	1.73e-05	0.000154	CcSEcCtD
Capecitabine—Hypersensitivity—Prednisone—systemic scleroderma	1.71e-05	0.000152	CcSEcCtD
Capecitabine—Dyspepsia—Methotrexate—systemic scleroderma	1.71e-05	0.000152	CcSEcCtD
Capecitabine—Decreased appetite—Methotrexate—systemic scleroderma	1.69e-05	0.00015	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	1.67e-05	0.000149	CcSEcCtD
Capecitabine—Fatigue—Methotrexate—systemic scleroderma	1.67e-05	0.000149	CcSEcCtD
Capecitabine—Asthenia—Prednisone—systemic scleroderma	1.67e-05	0.000148	CcSEcCtD
Capecitabine—Pain—Methotrexate—systemic scleroderma	1.66e-05	0.000147	CcSEcCtD
Capecitabine—Pruritus—Prednisone—systemic scleroderma	1.64e-05	0.000146	CcSEcCtD
Capecitabine—Feeling abnormal—Methotrexate—systemic scleroderma	1.6e-05	0.000142	CcSEcCtD
Capecitabine—Diarrhoea—Prednisone—systemic scleroderma	1.59e-05	0.000141	CcSEcCtD
Capecitabine—Gastrointestinal pain—Methotrexate—systemic scleroderma	1.59e-05	0.000141	CcSEcCtD
Capecitabine—Urticaria—Methotrexate—systemic scleroderma	1.54e-05	0.000137	CcSEcCtD
Capecitabine—Dizziness—Prednisone—systemic scleroderma	1.53e-05	0.000136	CcSEcCtD
Capecitabine—Abdominal pain—Methotrexate—systemic scleroderma	1.53e-05	0.000136	CcSEcCtD
Capecitabine—Body temperature increased—Methotrexate—systemic scleroderma	1.53e-05	0.000136	CcSEcCtD
Capecitabine—Vomiting—Prednisone—systemic scleroderma	1.48e-05	0.000131	CcSEcCtD
Capecitabine—Rash—Prednisone—systemic scleroderma	1.46e-05	0.00013	CcSEcCtD
Capecitabine—Dermatitis—Prednisone—systemic scleroderma	1.46e-05	0.00013	CcSEcCtD
Capecitabine—Headache—Prednisone—systemic scleroderma	1.45e-05	0.000129	CcSEcCtD
Capecitabine—Hypersensitivity—Methotrexate—systemic scleroderma	1.43e-05	0.000127	CcSEcCtD
Capecitabine—Asthenia—Methotrexate—systemic scleroderma	1.39e-05	0.000124	CcSEcCtD
Capecitabine—Nausea—Prednisone—systemic scleroderma	1.38e-05	0.000122	CcSEcCtD
Capecitabine—Pruritus—Methotrexate—systemic scleroderma	1.37e-05	0.000122	CcSEcCtD
Capecitabine—Diarrhoea—Methotrexate—systemic scleroderma	1.33e-05	0.000118	CcSEcCtD
Capecitabine—Dizziness—Methotrexate—systemic scleroderma	1.28e-05	0.000114	CcSEcCtD
Capecitabine—Vomiting—Methotrexate—systemic scleroderma	1.23e-05	0.00011	CcSEcCtD
Capecitabine—Rash—Methotrexate—systemic scleroderma	1.22e-05	0.000109	CcSEcCtD
Capecitabine—Dermatitis—Methotrexate—systemic scleroderma	1.22e-05	0.000109	CcSEcCtD
Capecitabine—Headache—Methotrexate—systemic scleroderma	1.22e-05	0.000108	CcSEcCtD
Capecitabine—Nausea—Methotrexate—systemic scleroderma	1.15e-05	0.000102	CcSEcCtD
